Clinically relevant molecular subtypes in leiomyosarcoma

Xiangqian Guo, Vickie Y. Jo, Anne M. Mills, Shirley X. Zhu, Cheng Han Lee, Inigo Espinosa, Marisa R. Nucci, Sushama Varma, Erna Forgó, Trevor Hastie, Sharon Anderson, Kristen Ganjoo, Andrew H. Beck, Robert B. West, Christopher D. Fletcher, Matt Van De Rijn

Research output: Contribution to journalArticleResearchpeer-review

59 Citations (Scopus)

Abstract

© 2015 American Association for Cancer Research. Purpose: Leiomyosarcoma is a malignant neoplasm with smooth muscle differentiation. Little is known about its molecular heterogeneity and no targeted therapy currently exists for leiomyosarcoma. Recognition of different molecular subtypes is necessary to evaluate novel therapeutic options. In a previous study on 51 leiomyosarcomas, we identified three molecular subtypes in leiomyosarcoma. The current study was performed to determine whether the existence of these subtypes could be confirmed in independent cohorts. Experimental Design: Ninety-nine cases of leiomyosarcoma were expression profiled with 30end RNA-Sequencing (3SEQ). Consensus clustering was conducted to determine the optimal number of subtypes. Results: We identified 3 leiomyosarcoma molecular subtypes and confirmed this finding by analyzing publically available data on 82 leiomyosarcoma from The Cancer Genome Atlas (TCGA). We identified two new formalin-fixed, paraffin-embedded tissue-compatible diagnostic immunohistochemical markers; LMOD1 for subtype I leiomyosarcoma and ARL4C for subtype II leiomyosarcoma. A leiomyosarcoma tissue microarray with known clinical outcome was used to show that subtype I leiomyosarcoma is associated with good outcome in extrauterine leiomyosarcoma while subtype II leiomyosarcoma is associated with poor prognosis in both uterine and extrauterine leiomyosarcoma. The leiomyosarcoma subtypes showed significant differences in expression levels for genes for which novel targeted therapies are being developed, suggesting that leiomyosarcoma subtypes may respond differentially to these targeted therapies. Conclusions: We confirm the existence of 3 molecular subtypes in leiomyosarcoma using two independent datasets and show that the different molecular subtypes are associated with distinct clinical outcomes. The findings offer an opportunity for treating leiomyosarcoma in a subtype-specific targeted approach.
Original languageEnglish
Pages (from-to)3501-3511
JournalClinical Cancer Research
Volume21
Issue number15
DOIs
Publication statusPublished - 1 Aug 2015

Fingerprint Dive into the research topics of 'Clinically relevant molecular subtypes in leiomyosarcoma'. Together they form a unique fingerprint.

Cite this